Baidu
map

李克强:推进突出临床实践的职称评定

2020-09-10 中国政府网 中国政府网

9月9日,第36个教师节前夕,李克强总理主持召开国务院常务会议,决定开展以能力为导向的考试评价改革,推进突出临床实践的职称评定。

9月9日,第36个教师节前夕,李克强总理主持召开国务院常务会议,决定开展以能力为导向的考试评价改革,推进突出临床实践的职称评定。

当天会议部署加快医学教育创新发展,为维护人民健康提供人才保障。

李克强说,我国医护人才总量、结构都还不适应健康中国建设需要。此次疫情更加显现出公共卫生、重症救治和护理等方面人才不足。要加大医学教育改革创新力度,增强医护人才保障。

临床医学要注重临床实践

李克强说,据我了解,现在医师职称评定没有论文是过不了关的,这是一个“硬杠杠”。所以医生们为了评定职称,把相当多的精力用于写论文上,临床实践反倒少了。而临床医学和其他学科不一样,临床实践和临床病例非常重要。因此,要开展以能力为导向的考试评价改革,推进突出临床实践的职称评定。”

当天会议决定,要提升医学人才培养质量。建立临床实践保障机制,加强高校附属医院临床教学职能,推进医学生早临床多临床反复临床。建立中医药跟师临床学习制度。要围绕提升临床实践能力健全住院医师规范化培训制度,对经住院医师培训合格的本科学历临床医师,在岗位聘用、职称晋升等方面与相关专业硕士研究生同等对待。

公共卫生不能简单理解为就是传染病防治,而应从国民健康角度进行拓展

李克强指出,加快医学教育创新发展,加快高水平公共卫生人才培养,深化医学院校与疾控中心、传染病医院的医教研合作。

“公共卫生不能简单地理解为就是传染病防治,而应从国民健康角度进行拓展。”总理说,“今天我们提倡全民健康,就是要从预防疾病、锻炼身体做起。此次疫情期间,专家们倡导要饮食营养均衡、加强体育锻炼等,这些都涉及公共卫生。”

李克强说,公共卫生不仅包括医疗,还与日常体育健身等密切相关。在一些发达国家,健康产业已形成国民经济的第一大产业。当前,我国已进入中等收入国家行列,人民群众在这方面的意愿和需求不断提升,健康产业潜力巨大,要把这篇文章做好。

当天会议决定,优化医护人才培养结构。加快培养防治结合的全科医学人才,医学院校要普遍开展面向全体医学生的全科医学教育,逐步扩大服务基层的定向免费全科医学生培养规模,中央财政继续支持为中西部乡镇卫生院培养本科定向医学生。扩大麻醉、感染、重症、儿科研究生招生规模。提高中医药专业教学中经典课程比重。

“三分治疗,七分护理”,要高度重视护理人才培养

李克强指出,加快医学教育创新发展,要在医护人才培养的某些薄弱环节上,加大补短板力度。

“当前突出的短板之一就是护理人才紧缺。今年初我到武汉金银潭医院考察时,就有医生向我反映抗疫中护士力量急需加强,所以我们马上从全国再增调医护人员特别是护士支援武汉。”总理说,“‘三分治疗,七分护理’,护理在医护工作中十分重要,而且工作十分辛劳。抗疫初期防护设备十分紧缺,不少护士穿着防护服在重症监护室照料病人,一进去就十个小时左右。”

李克强要求,要高度重视护理人才培养,大力发展高职护理教育,增强一线护理力量。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1004289, encodeId=0e8d1004289d0, content=过了一年了,还是没有什么动静,虽然这是正途,但是政策上一会左、一会右、非常坑人, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Sat Jul 31 21:48:18 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709581, encodeId=e8381e0958187, content=<a href='/topic/show?id=444d8066009' target=_blank style='color:#2F92EE;'>#职称评定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80660, encryptionId=444d8066009, topicName=职称评定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=032231754982, createdName=passed water, createdTime=Fri Nov 27 10:20:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324460, encodeId=b904132446000, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518344, encodeId=3a98151834460, content=<a href='/topic/show?id=74f180652b9' target=_blank style='color:#2F92EE;'>#职称#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80652, encryptionId=74f180652b9, topicName=职称)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3811138989, createdName=xxxx1053, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884590, encodeId=9e7e884590f5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Fri Sep 11 17:07:18 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2021-07-31 Ms🧐🧐🧐🧐🧐🧐

    过了一年了,还是没有什么动静,虽然这是正途,但是政策上一会左、一会右、非常坑人

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1004289, encodeId=0e8d1004289d0, content=过了一年了,还是没有什么动静,虽然这是正途,但是政策上一会左、一会右、非常坑人, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Sat Jul 31 21:48:18 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709581, encodeId=e8381e0958187, content=<a href='/topic/show?id=444d8066009' target=_blank style='color:#2F92EE;'>#职称评定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80660, encryptionId=444d8066009, topicName=职称评定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=032231754982, createdName=passed water, createdTime=Fri Nov 27 10:20:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324460, encodeId=b904132446000, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518344, encodeId=3a98151834460, content=<a href='/topic/show?id=74f180652b9' target=_blank style='color:#2F92EE;'>#职称#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80652, encryptionId=74f180652b9, topicName=职称)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3811138989, createdName=xxxx1053, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884590, encodeId=9e7e884590f5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Fri Sep 11 17:07:18 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1004289, encodeId=0e8d1004289d0, content=过了一年了,还是没有什么动静,虽然这是正途,但是政策上一会左、一会右、非常坑人, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Sat Jul 31 21:48:18 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709581, encodeId=e8381e0958187, content=<a href='/topic/show?id=444d8066009' target=_blank style='color:#2F92EE;'>#职称评定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80660, encryptionId=444d8066009, topicName=职称评定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=032231754982, createdName=passed water, createdTime=Fri Nov 27 10:20:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324460, encodeId=b904132446000, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518344, encodeId=3a98151834460, content=<a href='/topic/show?id=74f180652b9' target=_blank style='color:#2F92EE;'>#职称#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80652, encryptionId=74f180652b9, topicName=职称)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3811138989, createdName=xxxx1053, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884590, encodeId=9e7e884590f5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Fri Sep 11 17:07:18 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1004289, encodeId=0e8d1004289d0, content=过了一年了,还是没有什么动静,虽然这是正途,但是政策上一会左、一会右、非常坑人, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Sat Jul 31 21:48:18 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709581, encodeId=e8381e0958187, content=<a href='/topic/show?id=444d8066009' target=_blank style='color:#2F92EE;'>#职称评定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80660, encryptionId=444d8066009, topicName=职称评定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=032231754982, createdName=passed water, createdTime=Fri Nov 27 10:20:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324460, encodeId=b904132446000, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518344, encodeId=3a98151834460, content=<a href='/topic/show?id=74f180652b9' target=_blank style='color:#2F92EE;'>#职称#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80652, encryptionId=74f180652b9, topicName=职称)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3811138989, createdName=xxxx1053, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884590, encodeId=9e7e884590f5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Fri Sep 11 17:07:18 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-12 xxxx1053
  5. [GetPortalCommentsPageByObjectIdResponse(id=1004289, encodeId=0e8d1004289d0, content=过了一年了,还是没有什么动静,虽然这是正途,但是政策上一会左、一会右、非常坑人, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200606/779634fdc8944a13a6da20900ae58236/e941130f9cc742b19b7379e5a172b9c0.jpg, createdBy=97c65381808, createdName=Ms🧐🧐🧐🧐🧐🧐, createdTime=Sat Jul 31 21:48:18 CST 2021, time=2021-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709581, encodeId=e8381e0958187, content=<a href='/topic/show?id=444d8066009' target=_blank style='color:#2F92EE;'>#职称评定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80660, encryptionId=444d8066009, topicName=职称评定)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=032231754982, createdName=passed water, createdTime=Fri Nov 27 10:20:41 CST 2020, time=2020-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324460, encodeId=b904132446000, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1518344, encodeId=3a98151834460, content=<a href='/topic/show?id=74f180652b9' target=_blank style='color:#2F92EE;'>#职称#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80652, encryptionId=74f180652b9, topicName=职称)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7c3811138989, createdName=xxxx1053, createdTime=Sat Sep 12 14:20:41 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884590, encodeId=9e7e884590f5, content=支持, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201208/af76c3dece7248f2b297751d57470291/d45c15338e034c3f847da0bca70bfa4d.jpg, createdBy=3cfe1656094, createdName=cscs, createdTime=Fri Sep 11 17:07:18 CST 2020, time=2020-09-11, status=1, ipAttribution=)]
    2020-09-11 cscs

    支持

    0

相关资讯

从临床证据到临床实践,畅谈奥希替尼一线治疗

FLAURA研究显示,在EGFR突变阳性晚期非小细胞肺癌(NSCLC)一线治疗中,与标准EGFR-TKI(厄洛替尼或吉非替尼)10.2个月的中位无进展生存(PFS)相比,奥希替尼组中位PFS达到前所未有的18.9个月。基于这一研究结果,奥希替尼获批用于一线治疗,且越来越多的临床指南推荐其作为EGFR敏感突变NSCLC的一线优选方案。今年ESMO年会上,FLAURA研究的OS结果即将公布,并有望取得

Lancet:科学家建议将新分子成像技术应用于侵袭性癌症常规检查

科学家建议把比传统成像更准确的分子成像技术引入常规临床实践。

2019 NLA科学声明:临床实践中脂蛋白a的检测应用

脂蛋白a[Lp(a)]是公认的动脉粥样硬化性心血管疾病的危险因素,据统计,约有20%的人群存在Lp(a)水平升高。本文回顾了临床实践中脂蛋白a的检测的循证考虑并提出了应用Lp(a)水平指导一级预防和二级预防的治疗策略。

KEYNOTE-062引发的关于免疫治疗研究与临床实践的深度思考

北京消化肿瘤国际高峰论坛暨中国胃肠肿瘤临床研究协作组年会在北京隆重召开。北京大学肿瘤医院的沈琳教授担任大会主席,国内外学术领军人物济济一堂,就胃肠道肿瘤临床和转化研究的瓶颈、挑战及突破进行了深入的交流、研讨和展望。大会设有多个分会场,在食管癌/胃癌专场,来自北京大学肿瘤医院的张小田教授就“2019年ASCO胃癌研究进展”发表主题演讲,张教授的演讲中特别介绍了近来热议的KEYNOTE-062研究,这

直击ABC5:Eric P. Winer教授专访:新的研究成果改变进展期乳腺癌临床实践

ESO-ESMO 晚期乳腺癌第 5 届国际共识大会 (ABC5)在葡萄牙里斯本举行,该会议专注晚期乳腺癌诊疗进展并每2年更新一次指南。本次会议期间,肿瘤资讯非常荣幸邀请到乳腺癌治疗领域的世界级专家、丹娜法伯癌症研究所的Eric Paul Winer教授,Winer教授简要阐述了《ESO-ESMO晚期乳腺癌国际共识》与其他指南的不同之处,着力介绍了CDK4/6抑制剂、免疫治疗与TDM1三种治疗方法将

PACIFIC研究影响NSCLC免疫治疗临床实践,获益或不止步于Ⅲ期患者

Ⅲ期非小细胞肺癌(NSCLC)患者数量庞大,占所有NSCLC患者人数的1/3左右,其诊断相对复杂,治疗方式也多种多样。Ⅲ期不可手术NSCLC的5年生存率为约20%左右,其标准治疗为以铂类药物为基础的同步放化疗,然而在相当长一段时间内,大多数患者的临床结局未得到改善。PACIFIC研究的成功,打破了治疗的困局。广东省人民医院的乔贵宾教授对Ⅲ期NSCLC诊疗现状和免疫治疗临床实践等热点问题进行解读。

Baidu
map
Baidu
map
Baidu
map